Use of JAG2 expression in diagnosis of plasma cell disorders
First Claim
Patent Images
1. A method for diagnosis of a plasma cell disorder in an individual comprising detecting in a bone marrow sample comprising plasma cells from the individual, wherein the bone marrow sample is processed to enrich for plasma cells:
- a) JAG2 mRNA expression, orb) JAG2 protein;
wherein overexpression of JAG2 mRNA relative to a normal control, or overexpression of JAG2 protein relative to a normal control is indicative that the individual has a plasma cell disorder selected from the group consisting of monoclonal gammopathy of unknown significance (MGUS), smoldering myeloma, multiple myeloma and plasma cell leukemia.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention is based on the finding that plasma cell disorders such as Multiple Myeloma and Monoclonal Gammopathy of Unknown Significance are characterized by an increase in the expression of JAG2. Accordingly, the present invention provides a method for diagnosis of plasma cell disorders by detecting the expression or overexpression of JAG2. The expression or overexpression of JAG2 may be detected as increased mRNA transcripts or increased protein.
74 Citations
22 Claims
-
1. A method for diagnosis of a plasma cell disorder in an individual comprising detecting in a bone marrow sample comprising plasma cells from the individual, wherein the bone marrow sample is processed to enrich for plasma cells:
-
a) JAG2 mRNA expression, or b) JAG2 protein; wherein overexpression of JAG2 mRNA relative to a normal control, or overexpression of JAG2 protein relative to a normal control is indicative that the individual has a plasma cell disorder selected from the group consisting of monoclonal gammopathy of unknown significance (MGUS), smoldering myeloma, multiple myeloma and plasma cell leukemia. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
-
-
14. A method for determining a plasma cell disorder in an individual comprising the step of detecting in a bone marrow sample from the individual comprising plasma cells:
-
JAG2 protein expression, wherein expression of JAG2 protein of about 10 times greater than the level of JAG2 protein expression of a normal control is indicative of smoldering myeloma or MGUS, and wherein expression of JAG2 protein of about 100 times greater than the level of JAG2 protein expression of the normal control is indicative of multiple myeloma. - View Dependent Claims (15, 16, 17)
-
-
18. A kit for diagnosis of plasma cell disorder in sample comprising plasma cells, said kit comprising a pair of primers which specifically hybridize to a nucleic acid molecule encoding JAG2, and reagents for performing RT-PCR, wherein the sequences of the primer pair are SEQ ID NO:
- 1 and SEQ ID NO;
2.
- 1 and SEQ ID NO;
-
19. A kit useful for diagnosis of plasma cell disorder comprising a monoclonal antibody specific for the JAG2 protein, antigen binding fragments of the monoclonal antibody and combinations thereof;
- and regents for performing immunological detection, wherein the monoclonal antibody is reactive against the peptide of SEQ ID NO;
3. - View Dependent Claims (20, 21)
- and regents for performing immunological detection, wherein the monoclonal antibody is reactive against the peptide of SEQ ID NO;
-
22. A monoclonal antibody specific for JAG2 protein, wherein the monoclonal antibody thereby binds to plasma cells which express the JAG2 protein on the surface, and wherein the monoclonal antibody is reactive against the peptide of SEQ ID NO:
- 3.
Specification